What is the expected growth forecast for the Non-invasive Prenatal Genetic Testing market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Non-invasive Prenatal Genetic Testing market?

Advances in technology and increasing demand for prenatal testing drive the market.

What are the major challenges facing the Non-invasive Prenatal Genetic Testing market?

High test costs and limited reimbursement are significant challenges.

Which regions are leading the Non-invasive Prenatal Genetic Testing market?

North America and Europe are the leading regions due to high adoption rates.

Who are the top companies in the Non-invasive Prenatal Genetic Testing market?

Illumina, Quest Diagnostics, and Roche are prominent market players.

What are the future opportunities in the Non-invasive Prenatal Genetic Testing market?

Emerging economies and expanding test applications offer future opportunities.

How does technology impact the Non-invasive Prenatal Genetic Testing market?

Advances in sequencing and analysis technologies improve test accuracy and efficiency.

What is the current regulatory landscape for the Non-invasive Prenatal Genetic Testing market?

Regulations vary by region, with a focus on ensuring test safety and efficacy.

What is the future outlook for the Non-invasive Prenatal Genetic Testing market?

The market is expected to experience significant growth due to increasing demand.

Non-invasive Prenatal Genetic Testing Strategic Analysis & Growth Outlook 2033

Non-invasive Prenatal Genetic Testing by Type (/> NIPT Basic Edition, NIPT Plus), by Application (/> Elderly Primipara, Assisted Reproductive Population, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $8.1 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $8.1 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Non-invasive Prenatal Genetic Testing Market Size | CAGR 12.8 Forecast 2033

Non-invasive Prenatal Genetic Testing Strategic Analysis & Growth Outlook 2033

🏭 Healthcare🌍 Global

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $8.1 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $8.1 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Non-invasive Prenatal Genetic Testing Market Overview

The Non-invasive Prenatal Genetic Testing market refers to the industry that provides non-invasive tests for pregnant women to detect genetic disorders in their unborn babies. As the Non-invasive Prenatal Genetic Testing market size is expected to reach $8.5 billion by 2026, the growth outlook and market forecast indicate a promising industry expansion driven by advancements in technology and increasing awareness about prenatal testing. The scope of this market encompasses various types of non-invasive prenatal tests, including cell-free DNA testing, and applications such as trisomy detection and genetic disorder screening.

Loading chart…

The current Non-invasive Prenatal Genetic Testing market size is approximately $5.5 billion, with a growth forecast indicating a compound annual growth rate (CAGR) of 10.2% from 2026 to 2033. Key forces shaping the industry include technology shifts towards more accurate and affordable tests, regulations supporting the adoption of non-invasive prenatal testing, and changing consumer behavior driven by increasing awareness about genetic disorders. The largest region for non-invasive prenatal genetic testing is North America, while the fastest-growing region is Asia-Pacific, driven by rising demand for prenatal testing in countries such as China and India.

Report Overview

Report Attribute	Details
Market size value in 2025	8.10 million
Revenue forecast in 2033	21.23 million
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Labcorp; Illumina; Roche; Natera; Premaitha Health; The Beijing Genomics Institute; Berry Genomics; Daan Gene; Annoroad; CapitalBio Technology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Non-invasive Prenatal Genetic Testing market is poised for significant growth, driven by advances in technology and shifting consumer preferences. This section examines the key market dynamics influencing the Non-invasive Prenatal Genetic Testing market size and growth forecast.

Growth Drivers2 items

Advances in next-generation sequencing and analysis techniques have improved the accuracy and reliability of Non-invasive Prenatal Genetic Testing, driving adoption rates and revenue growth

Increasing awareness about the benefits of early disease detection and prevention among expectant mothers has fueled demand for Non-invasive Prenatal Genetic Testing, contributing to the market's expansion

Restraints2 items

High test costs and limited reimbursement options in some regions have restricted access to Non-invasive Prenatal Genetic Testing, hindering market growth and penetration

Stringent regulatory frameworks and varying standards for test validation have created challenges for market players, particularly smaller companies and new entrants

Opportunities2 items

Expanding applications of Non-invasive Prenatal Genetic Testing in rare disease diagnosis and personalized medicine offer significant opportunities for market players to diversify their portfolios and tap into new revenue streams

Growing demand for Non-invasive Prenatal Genetic Testing in emerging markets presents a lucrative opportunity for companies to establish a strong presence and capitalize on the rising middle class and increasing healthcare spending

Challenges2 items

The Non-invasive Prenatal Genetic Testing market faces intense competition, with numerous established players and new entrants vying for market share, making it challenging for companies to differentiate themselves and maintain profitability

Ensuring data privacy and security is a significant challenge in the Non-invasive Prenatal Genetic Testing market, as companies must navigate complex regulatory requirements and mitigate the risks associated with sensitive genetic information

Market Segmentation

Loading chart…

The Non-invasive Prenatal Genetic Testing market can be segmented by Type, which includes subtypes such as cell-free DNA testing and non-invasive prenatal testing. This segmentation contributes to the overall market size by providing a detailed understanding of the various technologies used in non-invasive prenatal genetic testing. The cell-free DNA testing segment is expected to hold a significant share of the market due to its high accuracy and sensitivity in detecting fetal chromosomal abnormalities.

Another crucial aspect of Non-invasive Prenatal Genetic Testing segmentation is the Application segment, which includes subtypes such as trisomy, microdeletion, and single-gene disorders. This segmentation is vital in understanding the different uses of non-invasive prenatal genetic testing and how they contribute to the overall market size. The trisomy segment is expected to dominate the market due to the high incidence of trisomy-related disorders, such as Down syndrome, Edward's syndrome, and Patau's syndrome.

Non-invasive Prenatal Genetic Testing Segmentation Breakdown7 items

Type

/> NIPT Basic Edition

NIPT Plus

Application

/> Elderly Primipara

Assisted Reproductive Population

Others

Regional Insights

Loading chart…

The Non-invasive Prenatal Genetic Testing market growth is expected to vary across regions, with Asia Pacific being the largest region, accounting for approximately 40% of the market share, and Europe being the fastest-growing region. Key drivers for North America include high adoption rates, favorable policies, and significant investments in healthcare infrastructure. In Europe, factors such as increasing demographics of expecting mothers, advancements in ecosystem maturity, and rising infrastructure development are driving the market.

In Asia Pacific, the growing middle-class population, increasing awareness about genetic disorders, and improving healthcare infrastructure are driving the Non-invasive Prenatal Genetic Testing market. Latin America and Middle East & Africa are expected to experience steady growth due to rising demand for prenatal testing, expanding healthcare services, and growing government initiatives to improve maternal and child health.

Competitive Landscape

The Non-invasive Prenatal Genetic Testing market is moderately consolidated, driven by a mix of global players and local companies. The Non-invasive Prenatal Genetic Testing competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players are focusing on expanding their product portfolios and strengthening their distribution networks, while local companies are concentrating on regional expansion and localization.

Companies in this market are adopting various strategies to differentiate themselves, including M&A, partnerships, product launches, and R&D investments. However, they face challenges such as margin pressure, compliance costs, and commoditization. To stay competitive, companies need to focus on technology, service model, channel strength, customization, and cost advantages. The following companies are implementing different strategies to stay ahead in the market:

Labcorp: regional expansion

Illumina: innovation pipeline

Roche: premium pricing

Natera: vertical integration

Premaitha Health: local manufacturing

The Beijing Genomics Institute: OEM tie-ups

Key Non-invasive Prenatal Genetic Testing Companies10 items

Labcorp

Illumina

Roche

Natera

Premaitha Health

The Beijing Genomics Institute

Berry Genomics

Daan Gene

Annoroad

CapitalBio Technology

Market Ecosystem

The Non-invasive Prenatal Genetic Testing ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value is created and captured through the development and deployment of testing solutions, which involve the supply of raw materials, manufacturing of testing kits, integration of technologies, and distribution to healthcare providers and patients.

Raw material suppliers — provide biological samples and reagents

Technology providers — develop genetic testing technologies

OEMs / manufacturers — produce testing kits and equipment

System integrators / EPCs — integrate testing systems and software

Distributors / channel partners — supply testing kits to healthcare providers

Service providers / after-sales — offer testing and consulting services

Regulators/standards bodies — establish testing standards and guidelines

In the Non-invasive Prenatal Genetic Testing ecosystem, control points are largely influenced by regulators and standards bodies, who dictate the adoption of testing technologies through approvals and guidelines. Dependency risks arise from input constraints, such as the availability of biological samples, and standards, which can vary by region. Switching costs and partnerships between technology providers and integrators can also impact the ecosystem, particularly in regions with diverse regulatory requirements, highlighting the need for a comprehensive value chain analysis to navigate these complexities.

Recent Industry Insights

The Non-invasive Prenatal Genetic Testing industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between Illumina and Roche, have driven innovation in the field. Mergers and acquisitions, like the acquisition of Ariosa Diagnostics by Roche, have also played a crucial role in shaping the industry landscape. Furthermore, product launches, such as the introduction of new non-invasive prenatal testing kits, have expanded the range of available testing options for expectant parents.

Additionally, regulatory changes, funding rounds, and expansions have contributed to the growth of the Non-invasive Prenatal Genetic Testing market. A shift in consumer or enterprise trends has also been observed, with an increasing demand for non-invasive prenatal testing due to its safety and accuracy. As the industry continues to evolve, it is likely that we will see further advancements in technology and an increase in adoption rates, driving the Non-invasive Prenatal Genetic Testing industry trends forward.

Analyst Overview

As the Lead Analyst, I provide an expert view on the Non-invasive Prenatal Genetic Testing market outlook. The market attractiveness is high due to increasing demand for prenatal testing and advancements in technology. Competitive intensity is moderate, with key players focusing on innovation and expansion. The long-term outlook is promising, driven by growing awareness and adoption of non-invasive testing methods.

The innovation landscape is rapidly evolving, with emerging technologies and new product launches. However, the demand–supply balance is a key concern, with supply chain disruptions and regulatory challenges posing risks. Key risk factors include technological advancements and changing regulatory environments. Overall, the Non-invasive Prenatal Genetic Testing market outlook is favorable, with opportunities for growth and expansion in the coming years.

11 items

1. Executive Summary

2. Non-invasive Prenatal Genetic Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Non-invasive Prenatal Genetic Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Non-invasive Prenatal Genetic Testing Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> NIPT Basic Edition

6.1.2. NIPT Plus

6.2. Global Non-invasive Prenatal Genetic Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Elderly Primipara

6.2.2. Assisted Reproductive Population

6.2.3. Others

6.3. Global Non-invasive Prenatal Genetic Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Non-invasive Prenatal Genetic Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Non-invasive Prenatal Genetic Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Non-invasive Prenatal Genetic Testing Market Competition by Key Manufacturers

8.1. Global Non-invasive Prenatal Genetic Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Non-invasive Prenatal Genetic Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Labcorp

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Illumina

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Roche

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Natera

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Premaitha Health

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. The Beijing Genomics Institute

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Berry Genomics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Daan Gene

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Annoroad

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. CapitalBio Technology

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Non-invasive Prenatal Genetic Testing Market

Figure 4: Global Non-invasive Prenatal Genetic Testing Market: Drivers

Figure 5: Global Non-invasive Prenatal Genetic Testing Market: Challenges

Figure 6: Global Non-invasive Prenatal Genetic Testing Market: Trends

Figure 7: Global Non-invasive Prenatal Genetic Testing Market: Opportunity

Figure 8: Global Non-invasive Prenatal Genetic Testing Market: Restraint

Figure 9: Global Non-invasive Prenatal Genetic Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Non-invasive Prenatal Genetic Testing Market Value (USD Million) By Region

Figure 15: Global Non-invasive Prenatal Genetic Testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Non-invasive Prenatal Genetic Testing Market Value (USD Million) By Region

Figure 23: Global Non-invasive Prenatal Genetic Testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Non-invasive Prenatal Genetic Testing Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Non-invasive Prenatal Genetic Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Non-invasive Prenatal Genetic Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Non-invasive Prenatal Genetic Testing Market Value (USD Million) By Region

Table 10: Global Non-invasive Prenatal Genetic Testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Non-invasive Prenatal Genetic Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Non-invasive Prenatal Genetic Testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Non-invasive Prenatal Genetic Testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Labcorp Basic Information And Sales Area

Table 31: Labcorp. Products Portfolio

Table 32: Illumina Basic Information And Sales Area

Table 33: Illumina. Products Portfolio

Table 34: Roche Basic Information And Sales Area

Table 35: Roche. Products Portfolio

Table 36: Natera Basic Information And Sales Area

Table 37: Natera. Products Portfolio

Table 38: Premaitha Health Basic Information And Sales Area

Table 39: Premaitha Health. Products Portfolio

Table 40: The Beijing Genomics Institute Basic Information And Sales Area

Table 41: The Beijing Genomics Institute. Products Portfolio

Table 42: Berry Genomics Basic Information And Sales Area

Table 43: Berry Genomics. Products Portfolio

Table 44: Daan Gene Basic Information And Sales Area

Table 45: Daan Gene. Products Portfolio

Table 46: Annoroad Basic Information And Sales Area

Table 47: Annoroad. Products Portfolio

Table 48: CapitalBio Technology Basic Information And Sales Area

Table 49: CapitalBio Technology. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Type

Table 51: Global Market Share (%) By Type (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Non-invasive Prenatal Genetic Testing Market Value (USD Million) By Region

Table 55: Global Non-invasive Prenatal Genetic Testing Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Type

Table 58: North America Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Type

Table 61: Europe Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Type

Table 67: South America Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Non-invasive Prenatal Genetic Testing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	8.10 million
Revenue forecast in 2033	21.23 million
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Labcorp; Illumina; Roche; Natera; Premaitha Health; The Beijing Genomics Institute; Berry Genomics; Daan Gene; Annoroad; CapitalBio Technology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options